-
Somatropin recombinant
- indication:For treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss
- pharmacologypharmacology:
- mechanism: hGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.
- toxicity:
- absorprion:
- halflife:
- roouteelimination: Although calcium excretion in the urine is increased, there is a simultaneous increase in calcium absorption from the intestine. Somatropin stimulates the synthesis of chondroitin sulfate and collagen, and increases the urinary excretion of hydroxyproline.
- volumedistribution:
- clearance: * 2.3 +/- 1.8 mL/min/kg [GHD patients (IV 33 ng/kg/min)]